Skip to main content
SpringerLink
Log in

Radiation protection in radionuclide therapies with 90Y-conjugates: risks and safety

  • Original article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The widespread interest in 90Y internal radionuclide treatments has drawn attention to the issue of radiation protection for staff. Our aim in this study was to identify personnel at risk and to validate the protection devices used.

Methods

90Y-MoAb (Zevalin, 15 cases, 1.1 GBq/patient) and 90Y-peptide (90Y-DOTATOC) systemic (i.v., 50 cases, 3.0 GBq/patient) and locoregional (l.r., 50 cases, 0.4 GBq/patient) treatments were considered. Radiolabelling was carried out in a dedicated hot cell. Tele-tongs, shielded (PMMA: polymethylmethacrylate) syringes/vials and an automatic dose fractionating system were used. Operators wore anti-X-ray and anti-contamination gloves, with TLD dosimeters placed over the fingertips. For i.v. administration, activity was administered by a dedicated system; for l.r. administration, during activity infusion in the brain cavity, tongs were used and TLDs were placed over the fingertips. The air kerma-rate was measured around the patients.

Results

The use of devices provided a 75% dose reduction, with mean fingertip doses of 2.9 mGy (i.v. MoAbs), 0.6 mGy (i.v. peptides)/radiolabelling procedure and 0.5 mGy/l.r. administration. The mean effective dose to personnel was 5 μSv/patient. The air kerma-rate around the patients administered i.v. 90Y-peptides were 3.5 (1 h) and 1.0 (48 h) μGy/h at 1 m. Patient hospitalisation of 6 h (l.r.)/48 h (i.v.) guaranteed that the recommended limits of 3 mSv/year to family members and 0.3 mSv/year to the general population (Council Directive 97/43/Euratom) were respected.

Conclusions

When specific procedures are adopted, a substantial improvement in 90Y manipulation is attainable, reducing doses and increasing safety. For the widespread clinical use of 90Y-conjugates, a completely automatic labelling procedure is desirable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Delacroix D, Guerre JP, Leblanc P, Hickman C. Radionuclide and radiation protection data handbook 2002, 2nd edition. Rad Prot Dos 2002;98:1–168

    Google Scholar 

  2. Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1038–1046

    Article  PubMed  CAS  Google Scholar 

  3. Schumacher T, Hofer S, Eichhorn K, Wasner M, Zimmerer S, Freitag P, et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging 2002;29:486–493

    Article  PubMed  CAS  Google Scholar 

  4. Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F, et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med Mol Imaging 1999;26:348–357

    Article  CAS  Google Scholar 

  5. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 2002;20:3262–3269

    Article  PubMed  CAS  Google Scholar 

  6. Wagner HN, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM, et al. Administration guidelines for radioimmunotherapy of non-Hodgkin’s lymphoma with 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002;43:267–272

    PubMed  CAS  Google Scholar 

  7. Tosi G. Report on one accident occurred in a nuclear medicine department in Italy. In: Proceedings of the 6th European ALARA Network workshop. Occupational Exposure Optimisation in the Medical Field and Radiopharmaceutical Industry. Sponsored by the European Commission Radiation protection. Madrid; 2002;225

  8. Salako QA, DeNardo SJ. Radioassay of yttrium-90 radiation using the radionuclide dose calibrator. J Nucl Med 1997;38:723–726

    PubMed  CAS  Google Scholar 

  9. Siegel JA, Zimmerman BE, Kodimer K, Dell MA, Simon WE. Accurate dose calibrator activity measurement of 90Y-ibritumomab tiuxetan. J Nucl Med 2004;45:450–454

    PubMed  CAS  Google Scholar 

  10. Zimmerman BE, Cessna JT. Experimental determinations of commercial ‘dose calibrator’ settings for nuclides used in nuclear medicine. Appl Radiat Isot 2000;52:615–619

    Article  PubMed  CAS  Google Scholar 

  11. Council Directive 97/43/Euratom 1997 on health protection of individuals against the dangers of ionising radiation in relation to medical exposure. Available on http://europa.eu.int/comm/energy/nuclear/ radioprotection/doc/legislation/9743_en.pdf

  12. Actuation of the Council Directive 97/43/Euratom 1997 in the Italian regulation (Decreto Legislativo 26 maggio 2000, n. 187. Attuazione della direttiva 97/43/EURATOM in materia di protezione sanitaria delle persone contro i pericoli delle radiazioni ionizzanti connesse ad esposizioni mediche). Available on http://www.camera.it/ parlam/leggi/deleghe/testi/00187dl.htm

  13. Zanzonico PB, Binkert BL, Goldsmith SJ. Bremsstrahlung radiation exposure from pure beta-ray emitters. J Nucl Med 1999;40:1024–1028

    PubMed  CAS  Google Scholar 

  14. Aubert B, Guilabert N, Lamon A, Ricard M. Which protection against radiation for new protocols of internal radiotherapy by 90Y. In: Proceedings of the 6th European ALARA Network workshop. Occupational Exposure Optimisation in the Medical Field and Radiopharmaceutical Industry. Sponsored by the European Commission Radiation protection. Madrid 2002;47–49

  15. Sarfaraz M, Kennedy AS, Cao ZJ, Sackett GD, Yu CX, Lodge MA, et al. Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors. Med Phys 2003;30:199–203

    Article  PubMed  CAS  Google Scholar 

  16. Stabin M, Siegel J, Lipsztein J, Hunt J, Brill A, Sparks R, et al. RADAR (RAdiation Dose Assessment Resource). http://www.doseinfo-radar.com; http://www.ieo.it/radar

  17. Saether HK, Davidson TM, Widmark A, Wohni T. Measurements of finger doses in x-ray guided surgery, nuclear medicine and research. Radiat Prot Dosimetry 2005;113:392–395

    Article  PubMed  CAS  Google Scholar 

  18. Cremonesi M, Ferrari M, Sacco E, Rossi A, Leonardi L, Chinol M, et al. Radiation protection in radioguided surgery of breast cancer. Nucl Med Commun 1999;20:919–925

    PubMed  CAS  Google Scholar 

  19. Release of patients after therapy with unsealed radionuclides. International Commission on Radiological Protection, ICRP Publication 94, 2005. http://www.elsevier.com

Download references

Acknowledgement

The authors are especially grateful to William Russell Edu for English revision.

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti, 435, 20141, Milan, Italy

    Giovanni Paganelli, Marco Chinol, Mirco Bartolomei & Gennaro Prisco

  2. Division of Medical Physics, European Institute of Oncology, Milan, Italy

    Marta Cremonesi, Mahila Ferrari, Annalisa Rossi & Giampiero Tosi

Authors
  1. Marta Cremonesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahila Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giovanni Paganelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Annalisa Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marco Chinol
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mirco Bartolomei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gennaro Prisco
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giampiero Tosi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Paganelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cremonesi, M., Ferrari, M., Paganelli, G. et al. Radiation protection in radionuclide therapies with 90Y-conjugates: risks and safety. Eur J Nucl Med Mol Imaging 33, 1321–1327 (2006). https://doi.org/10.1007/s00259-006-0151-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-006-0151-1

Keywords

Search

Navigation